ArticleJournal of gastroenterology2026
A steadily increasing trend in the incidence of esophageal adenocarcinoma in Akita Prefecture, Japan, through 2024.
Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Natural history of Barrett's esophagus over a 10-year period: a longitudinal endoscopic study in a Japanese population.Journal of gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA population-based study of esophageal adenocarcinoma (EAC) incidence in Akita Prefecture (2007-2014) revealed a surge beginning around 2010. Using the same registry, we extended the analysis through 2024 to examine recent EAC trends in the prefecture.
methodsWe used the Akita Prefecture collaborative, hospital-based cancer registry, which captures > 90% of cancers in the region. Registered esophageal cancers were histologically classified as squamous cell carcinoma, EAC, and unspecified neoplasm. Temporal changes in the number of and proportion of EAC cases, as well as the age-standardized incidence rates (ASRs; per 100,000 person-years, directly standardized to the 1985 Japanese model population), were estimated for 2010-2024. The estimated annual percent change (EAPC) was also calculated.
resultsThe number of EAC cases increased from 38 (2010-2014) to 72 (2020-2024), and the proportion among all esophageal cancers rose from 2.3% to 4.7%. The ASR increased from 0.39 (2010-2014) to 0.45 (2015-2019) and 0.77 (2020-2024) per 100,000 person-years. From 2010 to 2024, ASR showed a significant upward trend (EAPC 8.37% [95% confidence interval, 4.32-12.57]; p < 0.0001), largely driven by men.
conclusionUsing the most recent data from Akita's hospital-based registry, we demonstrate that both the number and incidence of EAC approximately doubled between 2010-2014 and 2020-2024, indicating that the upward trend that began around 2010 has persisted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.